Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
Parker VER, Hoang T, Schlichthaar H, Gibb FW, Wenzel B, Posch MG, Rose L, Chang YT, Petrone M, Hansen L, Ambery P, Jermutus L, Heerspink HJL, McCrimmon RJ. Parker VER, et al. Among authors: jermutus l. Diabetes Obes Metab. 2022 Jul;24(7):1360-1369. doi: 10.1111/dom.14712. Epub 2022 Apr 25. Diabetes Obes Metab. 2022. PMID: 35403793 Free PMC article. Clinical Trial.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. Ambery P, et al. Among authors: jermutus l. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. Lancet. 2018. PMID: 29945727 Clinical Trial.
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
Asano M, Sekikawa A, Kim H, Gasser RA Jr, Robertson D, Petrone M, Jermutus L, Ambery P. Asano M, et al. Among authors: jermutus l. Diabetes Obes Metab. 2021 Aug;23(8):1859-1867. doi: 10.1111/dom.14412. Epub 2021 May 19. Diabetes Obes Metab. 2021. PMID: 33908687 Clinical Trial.
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP. Henderson SJ, et al. Among authors: jermutus l. Diabetes Obes Metab. 2016 Dec;18(12):1176-1190. doi: 10.1111/dom.12735. Epub 2016 Aug 15. Diabetes Obes Metab. 2016. PMID: 27377054 Free PMC article.
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ. Boland ML, et al. Among authors: jermutus l. Nat Metab. 2020 May;2(5):413-431. doi: 10.1038/s42255-020-0209-6. Epub 2020 May 21. Nat Metab. 2020. PMID: 32478287 Free PMC article.
Erratum. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care 2021;44:1433-1442.
Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P. Nahra R, et al. Among authors: jermutus l. Diabetes Care. 2022 Dec 1;45(12):3112. doi: 10.2337/dc22-er12. Diabetes Care. 2022. PMID: 36228195 Free PMC article. No abstract available.
81 results